Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.63 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 11/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16654055 | 1.00 | PRKDC (0.63) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL28551259 | 1.00 | PRKDC (0.63) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL29623963 | 1.00 | PRKDC (0.63) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL17874734 | 0.94 | PRKDC (0.57) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL17634671 | 0.94 | PRKDC (0.60) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL15339664 | 0.93 | PRKDC (0.55) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL17634581 | 0.93 | PRKDC (0.57) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL17634771 | 0.93 | PRKDC (0.55) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL15339608 | 0.92 | PRKDC (0.54) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 | |
| SCHEMBL15339626 | 0.92 | PRKDC (0.56) | PRKDCSLC40A1FAAHCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10716789-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-07-21 | — | — | US | claimed |
| EP-3424920-B1 | CO-CRYSTALS OF (S)-N-METHYL-8-(1-((2'-METHYL-[4,5'-BIPYRIMIDIN]-6-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-04-15 | — | — | EP | claimed |
| EP-3424920-A1 | CO-CRYSTALS OF (S)-N-METHYL-8-(1-((2'-METHYL-[4,5'-BIPYRIMIDIN]-6-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-01-09 | — | — | EP | claimed |
| US-20180325897-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2018-11-15 | — | — | US | claimed |
| US-10039761-B2 | Co-crystals and pharmaceutical compositions comprising the same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-08-07 | — | — | US | claimed |
| US-20160339024-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-24 | — | — | US | claimed |
| US-12031150-B2 | Methods, compositions and kits for increasing genome editing efficiency | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-07-09 | — | — | US | disclosed |
| US-12031150-B2 | Methods, compositions and kits for increasing genome editing efficiency | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4219462-A1 | METHODS, COMPOSITIONS AND KITS FOR INCREASING GENOME EDITING EFFICIENCY | Vertex Pharmaceuticals Incorporated (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230022146-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-26 | — | — | US | disclosed |
| US-20220186216-A1 | Compositions and Methods for Treatment of Disorders Associated with Repetitive DNA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220088043-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-03-24 | — | — | US | disclosed |
| US-11124805-B2 | Methods, compositions and kits for increasing genome editing efficiency | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-21 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124805-B2 | Methods, compositions and kits for increasing genome editing efficiency | MRE11, DCLRE1B, XRCC6 | PRKDC 46/4885SLC40A1 4631/4885FAAH 4251/4885 |
| US-20140045869-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-20160339024-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SUCNR1, SDHA, SDHB | PRKDC 4779/4885SLC40A1 599/4885FAAH 408/4885 |
| US-12031150-B2 | Methods, compositions and kits for increasing genome editing efficiency | DCLRE1B, XRCC6, MRE11 | PRKDC 30/4885SLC40A1 4582/4885FAAH 4171/4885 |
| US-20230022146-A1 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | HBB, HBG1, HBG2 | PRKDC 417/4885SLC40A1 1850/4885FAAH 3987/4885 |
| US-10716789-B2 | Co-crystals and pharmaceutical compositions comprising the same | SUCNR1, SDHA, SDHB | PRKDC 4779/4885SLC40A1 599/4885FAAH 408/4885 |
| US-10039761-B2 | Co-crystals and pharmaceutical compositions comprising the same | SUCNR1, SDHA, SDHB | PRKDC 4779/4885SLC40A1 599/4885FAAH 408/4885 |
| US-20220088043-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | TOP2B, TOP2A, TOP1 | PRKDC 211/4885SLC40A1 3063/4885FAAH 4013/4885 |
| US-20130281431-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885SLC40A1 4477/4885FAAH 3955/4885 |
| US-20180325897-A1 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SUCNR1, SDHA, SDHB | PRKDC 4779/4885SLC40A1 599/4885FAAH 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.